Down-regulation of METTL3, a primary m6A methyltransferase, has been shown to promotes sorafenib resistance in HCC by reducing FOXO3 mRNA stability through m6A modification, leading to the activation of autophagy-associated pathways and enhanced expression of angiogenesis genes 45. This evidence concerns the gene METTL3 and hepatocellular carcinoma.